Dataset from A Randomized, Doubled-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of Fluticasone Furoate Nasal Spray 55 mcg and 110 mcg for 4 Weeks in Chinese Pediatric Subjects Ages 2 to 12 Years With Allergic Rhinitis

This Phase IV interventional study is a multi-center, randomized, double-blind,
placebo-controlled parallel study to evaluate the efficacy and safety of FFNS110 mcg and 55
mcg once daily versus vehicle placebo aqueous nasal spray in chinese pediatric subjects ages
2 to 12 years with AR.

This study comprises screening and run-in period (4 to14 days), double-blind treatment period
(28 days) and follows up period (3 to7 days). Subjects entering the study will participate
for maximum of 50 days, including five clinical visits and a follow-up contact.

The study is planned to enroll approximately 360 subjects.